Diagnosis
3What is AL amyloidosis?
Plain-language primer on AL amyloidosis, why early diagnosis matters so much, and how modern therapy works.
What is heart failure?
Plain-language primer on heart failure, why the modern therapy is built around four foundational classes, and what is changing.
What is type 1 diabetes?
Plain-language primer on type 1 diabetes, what is changing, and how modern therapy works.
Treatment
3PCSK9 inhibitors and modern lipid therapy explained
Plain-language primer on PCSK9 and the modern range of lipid-lowering options.
How obesity coverage frames are diverging between cardiovascular-prevention and obesity-only indications
GLP-1 obesity therapy coverage is bifurcating across markets between cardiovascular-prevention indication framing and obesity-only indication framing. The differences in coverage breadth, prior-authorisation criteria, and prescriber pathway are material and are reshaping commercial planning across the class.
Why HFpEF is the chapter cardiology has been waiting to write
Heart failure with preserved ejection fraction was a diagnostic and therapeutic puzzle for thirty years. The arrival of SGLT2 inhibitors with HFpEF outcome benefit, combined with a more nuanced phenotype framework and the GLP-1 obesity-HFpEF subgroup data, has turned a disease without a treatment into a disease with a small but growing set of evidence-based options.